Nanoscope Therapeutics Press Releases
-
Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference
January 20, 2025 by Wilson PJ
-
Nanoscope Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025 by Nanoscope Therapeutics
-
Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer
December 5, 2024 by Nanoscope Therapeutics
-
Nanoscope’s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress
December 2, 2024 by Nanoscope Therapeutics
-
Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia
November 11, 2024 by Nanoscope Therapeutics
-
Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors
November 7, 2024 by Nanoscope Therapeutics
-
Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa
October 31, 2024 by Nanoscope Therapeutics
-
Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration
October 21, 2024 by Nanoscope Therapeutics
-
Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024
October 15, 2024 by Nanoscope Therapeutics
-
Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa
October 10, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Licenses Optogenetic CatCh Technology
September 30, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona
September 19, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona
September 16, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration
September 12, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon
September 9, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 8, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 10, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect
June 19, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the BIO International Convention
May 29, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
May 14, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress
May 7, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
May 2, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
April 29, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
April 25, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024
April 17, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
March 26, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Participation in Upcoming Conferences
February 21, 2024 by Nanoscope Therapeutics
-
Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit
February 14, 2024 by Nanoscope Therapeutics
-
Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting
February 12, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting
February 7, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting
February 1, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa
January 18, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference
January 12, 2024 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board
December 4, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress
December 1, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII
November 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit
November 9, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023
November 3, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023
October 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.
October 26, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 13th The Eye and the Chip World Research Congress
October 10, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at The Retina Society 56th Annual Scientific Meeting
October 9, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations in Upcoming Conferences
October 2, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 4th Annual Gene Therapy for Ophthalmic Disorders Summit
September 28, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer
September 21, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Unveils Clinical Trial Results for MCO-010 in Treating Stargardt Disease
August 9, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 2023 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 21, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Participate in the Baird 2023 Biotech Discovery Series
June 12, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Participation in Upcoming Conferences
June 8, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the BIO International Convention
June 5, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress
May 22, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting
April 27, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
April 13, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
March 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor
March 20, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces World Health Organization Selection of “Sonpiretigene Isteparvovec” as International Nonproprietary Name for MCO-010
February 28, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing Board
February 13, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the BIO CEO & Investor Conference
February 2, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
January 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the Optogenetics and Optical Manipulation Conference
January 23, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the Next Generation Ophthalmic Drug Delivery Summit
January 19, 2023 by Nanoscope Therapeutics
-
Nanoscope’s Top Executive Team to Participate in Advanced Therapies Week
January 11, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Massoud Motamed, PhD, as VP of Quality
January 5, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 by Wilson PJ
-
Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease
November 10, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Expands Clinical and CMC Leadership Team with Gene Therapy Pharma Experience
November 7, 2022 by Nanoscope Therapeutics
-
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
October 18, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa
October 10, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 30, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 26, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
September 13, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting
September 8, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference
September 7, 2022 by Nanoscope Therapeutics
-
Nanoscope Announces Presentations at the 22nd Euretina Congress
August 29, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Present at the Retina Forum 2022
August 26, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Move Corporate Headquarters to Dallas
August 16, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
July 25, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit
July 14, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting
July 12, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting
July 11, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer
July 5, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains Award
June 27, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International
June 13, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Clinical Development of Optogenetics for Retinal Diseases to be Featured at Macula Society Meeting
June 6, 2022 by Nanoscope Therapeutics
-
Nanoscope Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors
May 25, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Clinical and Scientific Advances in Optogenetics to be Featured at ASGCT Annual Meeting, May 16-19, 2022 in Washington, DC
May 13, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Vision-Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as Part of ARVO Annual Meeting in Denver May. 1-4, 2022
April 26, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer
April 18, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces 3 New Appointments to its Scientific and Clinical Advisory Board
April 4, 2022 by Nanoscope Therapeutics
-
Nanoscope President to Present at Advancing Gene Therapy Summit March 30, 2022, in Boston, MA
March 28, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Elected to BIO Emerging Companies Section Governing Board
February 17, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics to present at 2022 BIO CEO & Investor Conference
February 11, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision
February 7, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Five New Clinical and Scientific Advisory Board Appointments
February 1, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patients
January 25, 2022 by Nanoscope Therapeutics
-
Nanoscope’s Vision Restoring Optogenetic Gene Therapy to be Featured in Four Presentations as part of SPIE Photonics West 2022
January 19, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Wins ‘2022 Biotech Innovation Award’
January 13, 2022 by Nanoscope Therapeutics
-
Nanoscope Awarded Key U.S. Patent Protecting Its Multi-Characteristic Opsin Gene Therapy Platform For Reversing Blindness
January 10, 2022 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Named Finalist for ‘Dallas Innovates and D CEO Magazine’ 2022 Innovation Award
December 22, 2021 by Nanoscope Therapeutics